Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orthofix Medical (OFIX) Gains from Sales and Divestitures (2011 - 2021)

Orthofix Medical (OFIX) reported Gains from Sales and Divestitures of $86542.0 for Q4 2021, up 16.89% year-on-year from $74036.0 in Q4 2020, and up 16.89% quarter-over-quarter from $74036.0 in Q4 2020.

Orthofix Medical (OFIX) has 11 years of Gains from Sales and Divestitures data on file, last reported at $86542.0 in Q4 2021.

  • For the quarter ending Q4 2021, Gains from Sales and Divestitures rose 16.89% year-over-year to $86542.0; the trailing twelve-month figure through Dec 2021 stood at $86542.0 (up 16.89% YoY), and the FY2021 full-year result was $86542.0, up 16.89% from the prior year.
  • Gains from Sales and Divestitures for Q4 2021 stood at $86542.0, up from $74036.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $157807.0 in Q4 2017 and bottomed at $27982.0 in Q4 2018.
  • A 5-year average of $78688.8 and a median of $74036.0 in 2020 frame the typical range for Gains from Sales and Divestitures.
  • Across the five-year window, Gains from Sales and Divestitures slumped 82.27% in 2018 and surged 68.24% in 2019, its largest moves.
  • Tracing OFIX's Gains from Sales and Divestitures over 5 years: stood at $157807.0 in 2017, then slumped by 82.27% to $27982.0 in 2018, then surged by 68.24% to $47077.0 in 2019, then surged by 57.27% to $74036.0 in 2020, then increased by 16.89% to $86542.0 in 2021.
  • According to Business Quant data, Gains from Sales and Divestitures over the past three periods registered $86542.0, $74036.0, and $47077.0 for Q4 2021, Q4 2020, and Q4 2019 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Abbott Laboratories 152.82 Bn 146.17 Bn 6.27 Bn
2 Stryker 115.07 Bn 112.19 Bn 3.81 Bn
3 Medtronic 95.25 Bn 87.08 Bn 5.76 Bn
4 Boston Scientific 71.38 Bn 70.17 Bn 3.61 Bn
5 Edwards Lifesciences 51.08 Bn 47.41 Bn 1.29 Bn
6 Koninklijke Philips 29.38 Bn 26.07 Bn 2.07 Bn
7 Dexcom 28.84 Bn 27.72 Bn 750.30 Mn
8 GE HealthCare Technologies 28.56 Bn 26.49 Bn 1.98 Bn
9 Steris 20.71 Bn 20.30 Bn 697.10 Mn
10 Orthofix Medical 375.38 Mn 254.51 Mn 139.55 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2021 86,542.00
Dec 31, 2021 86,542.00
Dec 31, 2020 74,036.00
Dec 31, 2020 74,036.00
Dec 31, 2019 47,077.00
Dec 31, 2019 47,077.00
Dec 31, 2018 27,982.00
Dec 31, 2018 27,982.00
Dec 31, 2017 157,807.00
Dec 31, 2017 157,807.00
Dec 31, 2016 171,451.00
Dec 31, 2016 171,451.00
Dec 31, 2015 183,216.00
Dec 31, 2015 183,216.00
Dec 31, 2014 84,396.00
Dec 31, 2014 84,396.00
Dec 31, 2013 62,948.00
Dec 31, 2013 62,948.00
Dec 31, 2012 28,336.00
Dec 31, 2012 28,336.00
Dec 31, 2011 36,647.00
Dec 31, 2011 36,647.00